These PROTACs were highly effective in degrading wild type ALK (DC50 of 10nM in H3122 cells and DC5 40 nM in Karpas 299 cells) and inhibiting the proliferation of anaplastic large cell lymphoma and non-small-cell lung cancer. Here, ALK is linked to non-small cell lung carcinoma.